Fundraising FoxSV7 Impact Medicine
Venture capitalLondon · 4 people tracked
Find your way into SV7 Impact Medicine
Sign up to see every warm intro you have to SV7 Impact Medicine
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SV7 Impact Medicine team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Fund manager profile
SV7 Impact Medicine is a venture fund manager based in London. SEC filings show 1 venture fund on record, most recently SV7 Impact Medicine Fund LP ($250M offering) filed June 2019.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 4 people
from public directories
What they invest in
from 1 of 1 portfolio companiesBiotech ×1Healthtech ×1
HQs:United States×1
Investments · 1 tracked
founders shown can be your intro path
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+9 more
Exits · 1
1 IPOsXilio TherapeuticsNASDAQ: XLO
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| SV7 Impact Medicine Fund, L.P.LPs: New Mexico Educational Retirement Board | 2019 | — | 16.2% | 1.50x | 0.62x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Xilio Therapeutics | 4.9% | $16.00 | Oct 2021 | $20.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is SV7 Impact Medicine located?
- SV7 Impact Medicine is headquartered in London.